BPC-157 and Rivaroxaban Interaction: What Patients and Clinicians Need to Know

What is the human evidence on BPC-157?

Thin. FDA concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. Its five human studies were small: a retrospective chart review of 17 patients given knee injections, in which 11 of 12 who received BPC-157 alone reported significant improvement, with no control group [4]; a single-arm pilot in 12 women with interstitial cystitis, in which 10 of 12 reported complete symptom resolution [5]; a two-person intravenous pilot [6]; and meeting abstracts [1]. A 2026 systematic review of orthopaedic and regenerative use found three studies covering 30 patients, all of poor methodological quality, with certainty of evidence rated very low [3].

What do the animal clotting findings show?

FDA reported clotting-time changes in 28-day intramuscular animal studies: BPC-157 shortened aPTT in rats and prolonged it in dogs, and also raised ALT, glucose and triglyceride levels. Longer studies and cancer-risk studies were not available [1]. The two species moved in opposite directions, and the effect in humans is unknown.

A two-person intravenous pilot reported no measurable change in the heart, liver, kidney, thyroid or glucose markers it tested, and no side effects; two people cannot establish safety [6].

What does rivaroxaban do on its own?

Rivaroxaban is an oral direct factor Xa inhibitor, a DOAC rather than warfarin. ROCKET AF randomized 14,264 people with non-valvular atrial fibrillation to rivaroxaban 20 mg daily or dose-adjusted warfarin; stroke or systemic embolism occurred in 1.7% versus 2.2% per year in the per-protocol analysis [2]. Major and nonmajor clinically relevant bleeding occurred in 14.9% versus 14.5% per year, with fewer intracranial and fatal bleeds on rivaroxaban [2]. The Xarelto label says drugs that impair hemostasis, such as aspirin, other antithrombotics and NSAIDs, raise the bleeding risk.

Could BPC-157 change rivaroxaban levels?

FDA found no human pharmacokinetic data for BPC-157 given orally, subcutaneously, nasally or on the skin [1]. After rectal enemas in two early studies the peptide was mostly undetectable in blood, and FDA judged it appears not to be absorbed systemically by that route [1].

Is BPC-157 an approved drug?

No. No FDA-approved product contains it, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. FDA's stated concerns on its compounding page include that it 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [7]. On July 23, 2026 FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation; the vote is nonbinding advice, and BPC-157 is not on the list [8].